Setiptiline

Drug Profile

Setiptiline

Alternative Names: MO-8282; MOD-20; ORG-8282; Tecipul; Tesolon

Latest Information Update: 18 Nov 2009

Price : $50

At a glance

  • Originator Organon
  • Developer Schering-Plough
  • Class Dibenzazepines; Tetracyclic antidepressants
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
  • 07 Jan 1997 Launched for Depression in Japan (PO)
  • 10 Dec 1996 A preclinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top